Trial Profile

A Phase I Clinical Trial of VXN-319 for the Prevention of Carbapenem Resistant Klebsiella Pneumoniae (crKP)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VXN 319 (Primary)
Indications Klebsiella infections
Focus Adverse reactions
Sponsors Idorsia Pharmaceuticals; Vaxxilon

Most Recent Events

26 Aug 2019 New trial record
20 Aug 2019 According to a Vaxxilon media release, the company has been awarded a grant of up to $1.4 million from CARB-X, with the possibility of $3.1 million more based on the achievement of milestones, to develop the first prophylactic vaccine for the prevention of carbapenem resistant Klebsiella pneumoniae (crKP).The complete CARB-X award will enable the company to conduct the full preclinical development, GMP manufacturing, and this phase I study of for VXN-319.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com